Olaparib for Stomach Cancer
This trial is testing a new cancer treatment that combines two existing treatments. The first part of the trial is to make sure the treatment is safe, and then they will assess how well it works.
- Stomach Cancer
- Gastroesophageal Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 4 trial • 181 Patients • NCT02476968
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the safeness profile of Olaparib for those undergoing treatment?
"Olaparib is believed to be moderately safe, and thus earned a score of 2. This assessment was made given that the drug has yet to pass efficacy testing though there is some evidence corroborating its safety profile."
Does this research endeavor permit those aged thirty and above to participate?
"As per the requirements of this clinical trial, individuals must be aged 18 or older but no more than 100 years old."
Who are the ideal candidates for this trial?
"This clinical trial is enrolling 26 individuals aged 18 to 100 suffering from gastroesophageal cancer. In order for patients to be eligible, they must meet the following requirements: being of legal age; having a primary tumor or an isolated metastatic site amenable to radiation in their stomach, esophagus, liver, lungs, pancreas thoracic/abdominal lymph nodes or soft tissues (biopsied sites should not be radiated); undergoing NGS testing at a CLIA certified laboratory with CAP tested and bioinformatics-validated protocols prior starting treatment; signing and dating the consent form; possessing one"
Is there currently any opportunity to enroll in this clinical trial?
"According to its clinicaltrials.gov page, this trial has closed recruitment as of May 19th 2022. However, there are still 643 other trials actively searching for candidates at the present moment."